CONCLUSIONS-IA-2 immunoreactivity in LADA patients has thus far been underestimated, and IA-2 (256 -760) autoantibody detection may represent a novel diagnostic tool for the identification of islet autoimmunity in these patients. Diabetes 57:
1276-1283, 2008
A utoimmune diabetes is characterized by the presence of circulating autoantibodies directed against several islet proteins, including insulin, GAD, and tyrosine phosphatase 2 (IA-2) (1). Among these diabetes-related autoantibodies, only GAD autoantibodies (GADAs) are not age dependent, thus representing a sensitive marker for the study of childhood and of adult autoimmune diabetes (2) . In addition, GADAs identify the subset of patients with type 2 diabetes who initially do not require insulin treatment but who may develop insulin dependency within a few years after diagnosis (3) (4) (5) . This form of diabetes has been variably indicated (6 -9) . Throughout this article, we refer to it as latent autoimmune diabetes in adults (LADA) (7) . The study of GAD65 antigenic target domains in Caucasian subjects with type 2 diabetes demonstrated that the presence of autoantibodies directed against the GAD COOHterminal epitopes is strongly associated with a type 1 diabetes phenotype (10, 11) . However, in Japanese LADA subjects (12) , a relationship between NH 2 -terminal binding of GADA and time to progression to insulin requirement was reported, suggesting that genetic background may influence GAD epitope-specific immunoreactivities in LADA patients. Although GADAs were shown to be the most sensitive marker to identify autoimmune diabetes in adult type 2 diabetes (3-5), they are not the sole isletrelated autoantibodies detected in these patients. IA-2 autoantibodies (IA-2As) were found in 2.2% of type 2 diabetic patients, and their presence, in addition to GADAs, increases the relative risk of these patients to require insulin therapy (13) . To date, IA-2As are detected using sensitive and specific radioimmunoassays, differing in terms of which of the radiolabeled IA-2 constructs is used, usually chosen among the full-length IA-2 FL (1-979) , the truncated NH 2 -terminally spliced IA-2 variant lacking exon 13 IA-2 BDC (256 -556:630 -979) and the intracytoplasmic IA-2 IC (605-979) construct (14, 15) . A recent study (16) showed that cytoplasmic IA-2 is the construct detecting IA-2As with the highest sensitivity in both newly diagnosed type 1 diabetic and pre-diabetic patients, thus suggesting that such construct should be used in type 1 diabetesrelated autoantibody screening studies. In the same study (16) , it was also demonstrated that IA-2 IC (605-979) immunoreactivity did not account for the whole anti-IA-2 humoral immune response in type 1 diabetes because other IA-2 constructs investigated showed additional immunoreactivities otherwise undetected by the IA-2 IC (605-979) construct. No data are currently available regarding which construct among IA-2 FL (1-979) , IA-2 BDC (256 -556:630 -979) , and IA-2 IC (605-979) has the highest sensitivity and specificity for detecting IA-2As in LADA patients and whether other IA-2 constructs may identify additional immunoreactivities in the sera of these patients. An association between IA-2 epitope specificities and age of onset in recent-onset Japanese type 1 diabetic and long-standing type 2 diabetic patients was demonstrated (17) . To our knowledge, no information is at present available on IA-2 epitope specificity in Caucasian LADA patients. On the basis of these and previous considerations, the aim of this study was to dissect the humoral autoimmune response to IA-2 in LADA patients of Caucasian origin. More specifically, we aimed to identify the IA-2 construct able to detect IA-2 immunoreactivity with the highest sensitivity in Caucasian LADA patients and to establish the frequency of autoimmune response against such construct in a large cohort of patients with type 2 diabetes. Finally, the epitope pattern of IA-2 immunoreactivity of LADA patients at disease diagnosis was compared with that of type 1 diabetic patients.
RESEARCH DESIGN AND METHODS
During the Non-Insulin Requiring Autoimmune Diabetes (NIRAD) study, a nationwide survey supported by the Società Italiana di Diabetologia aimed at assessing prevalence and characteristics of adult autoimmune diabetes in Italy in patients attending diabetes clinics with a clinical diagnosis of type 2 diabetes, 4,250 type 2 diabetic patients with a disease duration Ͻ5 years, with no insulin requirement and no evidence of ketosis for at least 6 months from diagnosis, were enrolled and screened for GAD and IA-2 IC (605-979) autoantibodies. One hundred ninety-one (4.5%) and 39 (0.9%) type 2 diabetic patients were found to be GADA and IA-2 IC (605-979) A positive, respectively (18) . Of the 4,250 NIRAD patients, 1,020 were collected at the "Sapienza" University of Rome (572 men and 406 women; age range 21.1-85.8 years [median 57.6 years]; mean disease duration 21.9 Ϯ 18.0 months). Forty-two (4.1%) and 13 (1.3%) of these 1,020 patients were GADA and IA-2 IC (605-979) A positive, respectively, whereas 978 patients were GADA and IA-2 IC (605-979) A negative.
In the first step of the present study, we aimed at evaluating which IA-2 constructs among the seven studied here had the highest sensitivity to detect humoral IA-2 immunoreactivity in Italian LADA patients. To this end, we analyzed all GADA ϩ LADA patient sera available from the NIRAD study (n ϭ 177: 92 men and 85 women; age range 23.7-86.6 years [median 54.3 years]; mean disease duration 24.0 Ϯ 18.8 months).
In the second step of the study, the immunoreactivity of the IA-2 (256 -760) construct, identified as the marker with the highest sensitivity for the detection of IA-2 autoantibodies in the group of GADA ϩ LADA patients, was analyzed in all abovementioned 1,020 samples (978 GADA Ϫ and IA-2 IC A Ϫ plus 42 GADA ϩ type 2 diabetic patients) screened at the "Sapienza" University of Rome during the NIRAD study.
In addition, among the abovementioned 1,020 patients, those found GADA or IA-2 (256 -760) A positive were tested for thyroid peroxidase autoantibodies (TPO-As) and, when possible, typed for HLA DRB1-DQB1 polymorphisms; 114 (for TPO-A) and 64 (for HLA polymorphisms) GADA Ϫ /IA-2 (256 -760) A Ϫ type 2 diabetic patients of comparable age and sex were analyzed as well.
Finally, in another set of experiments, we compared the IA-2 epitope target domains recognized at disease diagnosis by LADA, adult-onset, and childhoodonset type 1 diabetic sera. To this end, by using the seven constructs represented in Fig. 1 (19) . IA-2 constructs used in the study cDNAs encoding IA-2 (761-964) were amplified by PCR from full-length IA-2 using 5Ј-ACCATGAGCGATTACATCAACGCCA-3Ј and 5Ј-TCAGCAGCTACAGT CAGAATT-3Ј primers. Ligation and transformation of fresh PCR products were performed as previously described for IA-2 (256 -760) construct (16) . After purification, inserts were sequenced in both directions using an ABI 377 sequencer (Applied Biosystems, Foster City, CA). No deletions or truncations were found in this IA-2 construct. IA-2 BDC was prepared as reported previously (20) (13) 
sera, respectively, were analyzed from 10 type 2 diabetic patients. GADA detection. GADA in type 1 diabetic and LADA sera were detected by a slightly modified fluid-phase radioimmunoprecipitation assay (21) using a human recombinant full-length GAD65 construct furnished by Dr. Å. Lernmark (Department of Medicine, University of Washington, Seattle, WA). GADA assay obtained 80% sensitivity and 98% specificity at the 2007 4th DASP assay proficiency evaluation (lab 155). TPO-A. TPO-As were measured by a commercial radioimmunoassay kit (cod.14752; Adaltis, Roma, Italy). HLA class II genotyping. Genomic DNA was extracted using the salting-out method. High-resolution typing for DRB1*04 and DQB1 loci was performed using allele group-specific amplifications. A reverse line blot method, provided by H.A. Erlich and T. Bugawan (Roche Molecular System, Alameda, CA), was used as the detection system (22) . HLA genotypes were classified in three risk categories (high, moderate, and low) based on the absolute risk values for type 1 diabetes previously estimated in the Italian population (23) .
Statistical analysis
Statistical analyses were performed using SPSS software, version 13 (SPSS, Chicago, IL). Frequency differences were calculated by 2 test with Yates' correction, whenever appropriate, or by Fisher's exact test. A P value Ͻ0.05 was considered significant. (Fig. 3B) . IA-2 constructs used in international screenings. At disease diagnosis, IA-2 IC , IA-2 FL , and IA-2 BDC autoantibody frequencies (69.8, 62.3, and 62.3%, respectively) in childhood-onset type 1 diabetic patients (Fig. 3C) were significantly higher in comparison with adult-onset type 1 diabetic (45.3%, P Ͻ 0.02; 39.6%, P ϭ 0.03; and 30.2%, P Ͻ 0.002, respectively) and LADA patients (27.3%, P Ͻ 0.001; 27.3%, P ϭ 0.002; and 21.2%, P Ͻ 0.001, respectively).
RESULTS

IA-2 epitope immunoreactivities in GADA
DISCUSSION
IA-2 is one of the major autoantigens in type 1 diabetes, a target of both humoral (24 -28) and T-cell reactivity (29, 30) . IA-2As have also been detected in small percentages of type 2 diabetic patients but only in a few cases in addition to GADAs (18, 13) . IA-2A presence, in addition to GADA, increases the risk of LADA patients to require future insulin therapy (13) . The first aim of the present study was to identify the IA-2 construct able to detect IA-2 immunoreactivity with the highest sensitivity in Italian LADA GADA ϩ patients. We found that IA-2 IC (605-979) , at present considered as the most sensitive construct for IA-2A detection in autoimmune diabetes (16) , reacted with 19.8% of LADA patients investigated, a significantly lower percentage in comparison with the 29.4% of IA-2 (256 -760) , a construct used for the first time in LADA to investigate IA-2 middle-domain immunoreactivity. By the use of competition experiments, we showed that these two fragments represent distinct IA-2 immunoreactive epitopes. The different immunoreactivities of IA-2 IC (605-979) and IA-2 (256 -760) fragments seem to be related to the age at diagnosis; COOH-terminal domain of the IA-2 protein was found to be the major IA-2 autoantigenic region in childhood-onset type 1 diabetes, whereas in adult-onset type 1 diabetic and LADA GADA ϩ patients, there is a lower IA-2 COOH-terminal immunoreactivity that results in a significant decrease of diagnostic sensitivity of all IA-2 constructs containing a COOH-terminal residue. The finding that IA-2 (256 -760) construct reacts with more LADA patients than IA-2 FL (1-979) , even if the former is a portion of the latter, might be due to a different conformation of the 256 -760 amino acidic residues of the two constructs or to steric hindrances, ultimately leading to variable autoantibody binding affinities. Several studies demonstrated that IA-2As in type 1 diabetic patients are directed against multiple epitopes of the intracellular cytoplasmic portion of the protein (amino acids 601-979), located in the juxtamembrane region (JM, amino acids 605-682), and in the protein (PTP)-like COOH-terminal domain (amino acids 630 -979) (31) (32) (33) (34) (35) (36) . To date, an immune response against the extracellular domain of the IA-2 protein has not been demonstrated in type 1 diabetes. In our cohort of LADA patients, immunoreactivity against the IA-2 JM (601-630) fragment was almost three times less frequent than IA-2 (256 -760) construct, thus suggesting that the main epitopes target of IA-2A in LADA may be located either between amino acids 631 and 760 of the protein and/or, more interestingly, between amino acids 256 and 600, a domain comprising the extracellular portion of the protein.
The second aim of our study was to evaluate the frequency of IA-2 (256 -760) immunoreactivity in a large cohort of type 2 diabetic patients negative for GADA and IA-2 IC (605-979) A. Surprisingly, 33 of these patients were IA-2 (256 -760) A positive. To date, IA-2A presence in the absence of GADA has been considered a rare phenomenon in type 2 diabetes (13,37). However, our results clearly demonstrate that most IA-2 autoantibody screenings performed so far in type 2 diabetic patients underestimated the frequency of immunoreactivity against the IA-2 autoantigen and, as a consequence, the number of patients with autoimmunity. The double positivity for GAD and IA-2 autoantibodies in type 2 diabetes (11,37) suggests a pathogenetic link more consistent with type 1 rather than with type 2 diabetes, identifying patients who progress toward insulin dependency within a relatively brief period of time.
In the present study, we found that the LADA patients positive for GADA have significantly lower mean age and BMI and higher fasting glucose levels compared with type 2 diabetic patients negative for GADA and IA-2 (256 -760) A. IA-2 (256 -760) A positivity does not seem to determine a similar metabolic phenotype; however, genetic analysis demonstrates that LADA patients positive for GADA or IA-2 (256 -760) A have a significantly higher frequency of autoimmune diabetes HLA susceptible genotypes compared with type 2 diabetic patients negative for both GADA and IA-2 (256 -760) A.
GADA positivity in type 2 diabetic patients also identifies those at high risk for developing thyroid autoimmunity (38) . Interestingly, in our cohort of Caucasian patients, a similar result was found not only for GADA ϩ (18) but also for IA-2 (256 -760) A ϩ type 2 diabetic patients. TPO-A occurred significantly more frequently in IA-2 (256 -760) A ϩ (regardless of GADA positivity) than in islet-related autoantibody-negative type 2 diabetic patients, thus supporting the hypothesis that some of these patients may represent a phenotypic expression of a complex autoimmune polyendocrine syndrome.
Recently, it was shown that the islet proteins recognized by T-cells and autoantibodies in type 1 diabetic and LADA patients may be in part different (39) and that measures of multiple islet protein T-cell responses in type 2 diabetic patients may improve the identification of patients with autoimmune diabetes compared with autoantibody assess- ment alone (40) . It was hypothesized that the higher sensitivity of T-cell responses could be due to the capacity of T-cells to react with unknown islet antigens (40) . In that study, however, IA-2 immunoreactivity was evaluated with IA-2 IC (605-979) and not with IA-2 (256 -760) construct. It is possible that IA-2 (256 -760) A detection might contribute to reduce the bias of sensitivity between T-cell response and autoantibody analysis for identification of LADA patients.
It is also of potential interest that IA-2 (256 -760) construct contains in its sequence a number of IA-2 T-cell epitopes recognized by human CD4 T-cells (41) . Finally, our data, related to Caucasian patients, confirm and extend those reported in Japanese diabetic populations (17) , in which an association between IA-2 autoantibody epitope specificities and age at onset was found. These results suggest that the mechanisms responsible for the generation of IA-2A in Caucasian and Japanese LADA patients are similar and that different genetic backgrounds probably do not influence IA-2A epitope specificity, in contrast with what has been reported for GAD epitope immunoreactivity (12) .
In summary, by analyzing IA-2 epitope immunoreactivity in Caucasian LADA and type 1 diabetic patients, we found that 1) IA-2 (256 -760) , an IA-2 construct lacking the COOHterminal portion of the protein, may represent a new sensitive marker for the study of the humoral IA-2 immunoreactivity in LADA patients, by being able to identify IA-2 immunoreactivity also among GADA Ϫ type 2 diabetic patients; 2) IA-2 (256 -760) A presence is associated with increased risk for developing thyroid autoimmunity and higher frequency of autoimmune diabetes HLA susceptible genotypes; and 3) the specificity of IA-2 humoral immune response in autoimmune diabetic patients is related to the age at diagnosis, with an increased IA-2 COOH-terminal immunoreactivity in childhood-onset type 1 diabetes.
In conclusion, the results of the present study suggest that IA-2 immunoreactivity in type 2 diabetic and LADA patients is more frequent than previously demonstrated and that the analysis of IA-2 (256 -760) immunoreactivity in type 2 diabetic patients may represent an additional, important diagnostic tool for a more appropriate classification of diabetes. 
